Novogene Corporation Inc.

Novogene Corporation Inc., a minority-owned small business based in Sacramento, California, provides next-generation DNA and RNA sequencing, library preparation, and bioinformatics analysis services to federal research agencies exclusively as a prime contractor (100% of awards). The company operates across full-and-open federal procurement without reliance on set-aside vehicles, competing on technical merit and past performance despite its small-business designation.

Novogene's capability portfolio centers on high-throughput sequencing and genomic analysis spanning whole genome, transcriptome, metagenomic, single-cell RNA, and targeted amplicon sequencing using Illumina NovaSeq, PacBio, and related platforms. Representative work includes a $177 thousand shotgun metagenomics study of fecal samples from West Africans for the National Human Genome Research Institute; a $195.087 thousand transcriptomics analysis contract with the EPA's Office of Research and Development for studying emerging contaminants in laboratory-exposed frogs and fish; a $140 thousand genome sequencing award from USDA ARS for single-cell genomics on host-parasite interactions in livestock and rodents; and a $134.736 thousand Illumina sequencing services call from the U.S. Geological Survey supporting vertebrate species research. Recent awards include a $24.9 thousand pharmacogenomic analysis engagement with the National Institute on Drug Abuse for the STAR-B randomized clinical trial and an $18.171 thousand single-cell RNA sequencing contract from Veterans Integrated Service Network 21.

Customer concentration is diffuse across federal research institutions. The top five funding entities by award count account for 48% of Novogene's 319 total awards and span USDA Agricultural Research Service (62 awards, $828 thousand combined potential value), the National Institute of Allergy and Infectious Diseases (32 awards, $538 thousand), and three regional USDA ARS divisions totaling 60 awards. By dollar value, the top five agencies represent 46% of combined potential value, with USDA ARS Plains Area leading at $897 thousand across 21 awards. Novogene serves 44 distinct federal customer agencies, with NIH institutes and USDA comprising the dominant customer base. The National Cancer Institute, USGS, and National Institute of Child Health and Human Development round out the top five by potential value. This concentration reflects a research-services-focused footprint rather than defense or operations-focused federal work.

Novogene holds two named blanket purchase agreements. The primary vehicle is a $120 thousand single-award BPA with the U.S. Geological Survey (Office of Acquisitions and Grants) running through January 2027 for microbial DNA and microRNA library preparation and next-generation sequencing services supporting vertebrate species research; three task orders totaling $63 thousand have been issued against this agreement. A second BPA (1333ND18ANB630002) carries $140 thousand potential value with three task orders. Beyond these vehicles, Novogene operates through individual purchase orders and firm fixed-price calls issued directly by customer agencies, with no participation in government-wide contract vehicles such as GWACs or agency-wide IDIQs.

Activity has declined materially in recent years. Novogene averaged 33 awards annually in 2022–2023, dropped to 19 in 2024, and fell to 15 in 2025; only 3 awards appear in 2026 year-to-date. Combined potential value across the entire 319-award portfolio is $8 million, with $7.6 million obligated, indicating sustained invoicing but contracting volume compression. Six awards carrying $117 thousand in combined potential value complete within the next twenty-four months and face recompete exposure.

Novogene operates exclusively as a prime contractor with no subcontract footprint; the vendor does not sub to larger integrators. The company's capability categorization reflects its core specialization: 179 awards fall under Testing Laboratories and Services NAICS, 48 under Research and Development in Biotechnology (except Nanobiotechnology), and 31 under broader biotechnology R&D. Procurement service codes are dominated by Reference Laboratory Testing (105 awards) and Special Studies/Analysis—Scientific Data (88 awards), confirming a pure laboratory-services positioning in federal R&D spending rather than a systems or program-management role.